Sulpiride versus placebo for schizophrenia

Area of Science:

• Psychiatry
• Clinical Pharmacology

Background:

• Sulpiride, an older antipsychotic, is recognized for potentially fewer adverse effects and efficacy in treating negative symptoms of schizophrenia.
• Its neuropharmacological profile resembles newer atypical antipsychotics, and it is cost-effective.

Purpose of the Study:

• To assess the efficacy of sulpiride compared to placebo in patients diagnosed with schizophrenia and similar severe mental illnesses.

Main Methods:

• A systematic review of randomized controlled trials (RCTs) was conducted, searching the Cochrane Schizophrenia Group Trials Register and other sources.
• Two short-duration RCTs involving 113 participants compared sulpiride with placebo, with clinical global state response as the primary outcome.

Main Results:

• No significant differences were observed in positive or negative symptoms between sulpiride and placebo groups.
• One study indicated a potential improvement in social behavior with sulpiride, though data were limited.
• Few participants withdrew from the studies within three months.

Conclusions:

• Current randomized trial evidence for sulpiride's superiority over placebo in schizophrenia is very limited.
• Further high-quality research is needed to establish its clinical effectiveness and safety profile.